NOS1 and Duchenne muscular dystrophy: Their validation experiments performed in human myoblasts showed that their inhibition results in increased nNOS expression, thus implicating these miRNAs as modulators of nNOS activity and potential therapeutic targets to combat premature muscle fatigue in DMD patients [45].